Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
|
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis
    Gadaleta-Caldarola, Gennaro
    Lanotte, Laura
    Infusino, Stefania
    Gadaleta-Caldarola, Arianna
    Schipilliti, Francesca Matilde
    Citrigno, Claudia
    Petrarota, Cataldo
    Cusmai, Antonio
    Rizzo, Alessandro
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 37
  • [2] Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)
    Gupta, Gaurav
    Hussain, Md Sadique
    Pant, Kumud
    Ali, Haider
    Thapa, Riya
    Bhat, Asif Ahmad
    CURRENT CANCER DRUG TARGETS, 2025, 25 (02) : 108 - 112
  • [3] Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
    Fenn, K. M.
    Kalinsky, K.
    DRUGS OF TODAY, 2019, 55 (09) : 575 - 585
  • [4] Novel antibody-drug conjugates for triple negative breast cancer
    Nagayama, Aiko
    Vidula, Neelima
    Ellisen, Leif
    Bardia, Aditya
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [5] TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
    Dent, Rebecca A.
    Cescon, David W.
    Bachelot, Thomas
    Jung, Kyung Hae
    Shao, Zhi-Ming
    Saji, Shigehira
    Traina, Tiffany A.
    Vukovic, Petra
    Mapiye, Darlington
    Maxwell, Micah J.
    Schmid, Peter
    Cortes, Javier
    FUTURE ONCOLOGY, 2023, 19 (35) : 2349 - 2359
  • [6] Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives
    Sawant, Sanjana
    Naik, Gaurav Gopal
    Sahu, Alakh N.
    Jagtap, Vijay A.
    MEDICAL ONCOLOGY, 2024, 41 (12)
  • [7] Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates
    Kaboli, Parham Jabbarzadeh
    Shabani, Shima
    Sharma, Sagar
    Nasr, Minoo Partovi
    Yamaguchi, Hirohito
    Hung, Mien-Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (04): : 1671 - 1685
  • [8] Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
    Seligson, John M.
    Patron, Alexandra M.
    Berger, Michael J.
    Harvey, R. Donald
    Seligson, Nathan D.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (07) : 921 - 931
  • [9] Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs
    Tang, Qi
    Li, Hui
    Zhao, Xin Tong
    Li, Ze Ying
    Ma, Chun Xiao
    Zhou, Shao Qiang
    Chen, De Dian
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (04) : 527 - 542
  • [10] Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)
    Dri, Arianna
    Arpino, Grazia
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    Danesi, Romano
    De Laurentiis, Michelino
    Del Mastro, Lucia
    Fabi, Alessandra
    Generali, Daniele
    Gennari, Alessandra
    Guarneri, Valentina
    Santini, Daniele
    Simoncini, Edda
    Zamagni, Claudio
    Puglisi, Fabio
    CANCER TREATMENT REVIEWS, 2024, 123
12345